Five Good Canadian Dividend Stocks

Analysis Methodology

Refer to the blog post of November 27, 2019 for a description of the method used.

Candidates

As of November 27, 2019, the following companies from the universe of all TSX stocks have a dividend yield between 3.54% and 11.80% and have increased their dividend consecutively for at least five years:

AI
AQN
BCE
CGX
CM
CPX
CU.X
CUP.U
EIF
ENF
FCD.UN
INE
IPL
LB
MFC
NA
PEGI
PPL
RY
T
TCL.A
TCL.B
TD
UNS

Analysis

Dividend Coverage

We're looking for companies with positive coverage and less than 75%.
Possible companies include:

RY
TCL.A
TCL.B
NA
UNS
MFC

Valuation

We're looking for companies equal to or greater than one.
Possible companies include:

UNS
TCL.A
TCL.B
CGX
ENF
IPL
LB
CU.X
MFC
CM
TD
T
PPL
RY
BCE

Total Return

We're going to use a sweet spot criteria of greater than 10% and less than 20%. Companies include:

AQN
ENF
MFC
IPL
CU.X
TD
TCL.A
T
TCL.B
CPX
FCD.UN
RY
CM
PPL
NA
CGX
UNS
LB
EIF
BCE

The Trifecta

From a beginning portfolio 99 companies the final five that occupy the centre of this vend diagram are:

RY
TCL.A
TCL.B (low trading volume)
UNS
MFC

I bought all of them accept for TCL.B today. So fun to run.

Comments

11 Reasons Why INVRS is Better Than Excel Alone

If you work with your own investment models you likely use excel to build them, but excel isn’t ideal for many reasons and it costs you in other ways. First, you need good data and it isn’t just lying around in an easy to import format. You’re either keying it in yourself or paying money for excel downloads. When you need data from numerous sources – price information, data from different statements and across multiple years - you must merge it from multiple sheets. It's a n inefficient process which can lead to data corruption. After all this data is collected and merged, models built and tested, the net result is one statistic for one company. A stand-alone number without context has limited use. To be meaningful, you need to compare it to similar companies. This is just a sample of the challenges. You need software that overcomes these problems and is designed for investment model creation. Surprise! This software exists,

NextEra - Good Dividend in the Renewable Energy Sector

NextEra had good results relative to a group of peers in a factor-based analysis. NextEra has an appealing profitability and income profile. Its price momentum looks decent, with a caveat. Its relatively small size (a small mid-cap) coupled with its industry (renewable energy) further weight the odds that this company could be a strong performer in the future. If you want in on renewable energy, we recommend NextEra. The Analysis Overview I created a portfolio of stocks in the alternative energy sector, looking specifically for companies with a market cap over $1B but less than $4B. This is a sweet spot that offers strong potential for growth but is also substantial enough not to be too speculative. It's my believe that alternative energy is on the ascendance, where as fossil fuels will inevitably decline (NextEra isn't a pure play in this regard however, natural gas assets are part of its portfolio). If you share this belief and you want exposure to this ma

GlaxoSmithKline Scores High in Quality

I created a portfolio of the top pharmaceutical companies trading in the US and ran a quality of earnings analysis on them. With the highest possible score being nine, GSK scored the best with seven. Here are the results: Quality of Earnings - Major Pharmaceuticals Here's the balance of the companies in the portfolio. We can see that AZN was the worst at two. Quality of Earnings - Major Pharmaceuticals 2 Just for laughs, lets see how GSK and AZN have performed from a price perspective. Interestingly, AZN has been outperforming GSK. It'll be interesting to say if this trend will continue or if it will, more correctly I believe, reverse.

The INVRS Blog

Search This Blog